63 related articles for article (PubMed ID: 9842268)
21. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
Swinne D; Watelle M; Van der Flaes M; Nolard N
Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
[TBL] [Abstract][Full Text] [Related]
22. In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods.
Torres-Rodríguez JM; Alvarado-Ramírez E
J Antimicrob Chemother; 2007 Sep; 60(3):658-61. PubMed ID: 17623690
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B.
Anaissie E; Paetznick V; Proffitt R; Adler-Moore J; Bodey GP
Eur J Clin Microbiol Infect Dis; 1991 Aug; 10(8):665-8. PubMed ID: 1748123
[TBL] [Abstract][Full Text] [Related]
24. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
25. Tolerance to amphotericin B in clinical isolates of Candida tropicalis.
Barchiesi F; Maracci M; Baldassarri I; Spreghini E; Giannini D; Scalise G
Diagn Microbiol Infect Dis; 2004 Nov; 50(3):179-85. PubMed ID: 15541603
[TBL] [Abstract][Full Text] [Related]
26. [Sensitivity of clinical isolates of Candida albicans to 5-fluorocytosine].
Fernández Andreu CM; Lemus Molina D; Martínez Machín G
Rev Cubana Med Trop; 2000; 52(3):191-6. PubMed ID: 11826522
[TBL] [Abstract][Full Text] [Related]
27. Emergence of non-albicans Candida species and antifungal resistance in a tertiary care hospital.
Capoor MR; Nair D; Deb M; Verma PK; Srivastava L; Aggarwal P
Jpn J Infect Dis; 2005 Dec; 58(6):344-8. PubMed ID: 16377864
[TBL] [Abstract][Full Text] [Related]
28. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
Cheng MF; Yu KW; Tang RB; Fan YH; Yang YL; Hsieh KS; Ho M; Lo HJ
Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719
[TBL] [Abstract][Full Text] [Related]
29. Phenotypic characterization and in vitro antifungal sensitivity of Candida spp. and Malassezia pachydermatis strains from dogs.
Brito EH; Fontenelle RO; Brilhante RS; Cordeiro RA; Soares Júnior FA; Monteiro AJ; Sidrim JJ; Rocha MF
Vet J; 2007 Jul; 174(1):147-53. PubMed ID: 17188535
[TBL] [Abstract][Full Text] [Related]
30. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
Pappalardo MC; Szeszs MW; Martins MA; Baceti LB; Bonfietti LX; Purisco SU; Baez AA; Melhem MS
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):146-51. PubMed ID: 19345042
[TBL] [Abstract][Full Text] [Related]
32. Detection of resistance to amphotericin B in Candida isolates by using Iso-Sensitest broth.
Cuenca-Estrella M; Díaz-Guerra TM; Mellado E; Rodríguez-Tudela JL
Antimicrob Agents Chemother; 2001 Jul; 45(7):2070-4. PubMed ID: 11408225
[TBL] [Abstract][Full Text] [Related]
33. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
34. Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves.
Ralph ED; Khazindar AM; Barber KR; Grant CW
Antimicrob Agents Chemother; 1991 Jan; 35(1):188-91. PubMed ID: 2014976
[TBL] [Abstract][Full Text] [Related]
35. Comparative susceptibility of four kinds of pathogenic fungi to amphotericin B and amphotericin B methyl ester.
Huston AC; Hoeprich PD
Antimicrob Agents Chemother; 1978 Jun; 13(6):905-9. PubMed ID: 354519
[TBL] [Abstract][Full Text] [Related]
36. Thermal death potentiation by amphotericin B in Cryptococcus neoformans and its dependence on pre-incubation temperature.
Madeira-Lopes A
J Med Vet Mycol; 1986 Feb; 24(1):35-40. PubMed ID: 3517277
[TBL] [Abstract][Full Text] [Related]
37. New medium for in vitro susceptibility studies with amphotericin B.
Utz CJ; White S; Shadomy S
Antimicrob Agents Chemother; 1976 Oct; 10(4):776-7. PubMed ID: 791112
[TBL] [Abstract][Full Text] [Related]
38. Amphotericin B.
Abadi J
Pediatr Rev; 1995 Oct; 16(10):363-4. PubMed ID: 7479429
[No Abstract] [Full Text] [Related]
39. In vitro sensitivity to amphotericin B of Cryptococcus neoformans isolated in Thailand.
Gaew-Im M; Thasnakorn P
J Med Assoc Thai; 1971 Jan; 54(6):405-9. PubMed ID: 5171413
[No Abstract] [Full Text] [Related]
40. [Rapid detection of the sensitivity of Candida albicans to antibiotics].
Simonetti N; Cantani A
Antibiotica; 1969 Mar; 7(1):26-35. PubMed ID: 5397073
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
